JP Morgan Chase
CYCN icon

JP Morgan Chase’s Cyclerion Therapeutics CYCN Stock Holding History

JP Morgan Chase’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,067
Closed -$127K – 6691
2021
Q3 		$127K Sell
2,067
-922
-31% -$60.3K ﹤0.01% 5449
2021
Q2 		$233K Sell
2,989
-2,316
-44% -$145K ﹤0.01% 5154
2021
Q1 		$296K Buy
5,305
+851
+19% +$63.9K ﹤0.01% 4973
2020
Q4 		$273K Buy
4,454
+2,044
+85% +$139K ﹤0.01% 4692
2020
Q3 		$332K Buy
2,410
+2,034
+541% +$233K ﹤0.01% 4160
2020
Q2 		$44K Sell
376
-4
-1% -$334 ﹤0.01% 4866
2020
Q1 		$20K Sell
380
-45
-11% -$3.21K ﹤0.01% 4948
2019
Q4 		$23K Buy
425
+11
+3% +$1.03K ﹤0.01% 5298
2019
Q3 		$101K Buy
414
+44
+12% +$9.5K ﹤0.01% 4900
2019
Q2 		$83K Buy
+370
New +$105K ﹤0.01% 4997

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase's CYCN Position: Q4 2021 in Review

JP Morgan Chase sold out of Cyclerion Therapeutics (CYCN) in Q4 2021, closing a stake of 2,067 shares — an estimated $127K sold.

JP Morgan Chase first reported a position in CYCN in Q2 2019 and held it in 10 quarters. The position peaked at $332K in Q3 2020. 56 funds tracked by Wall St. Rank hold CYCN as of Q4 2021.

  • JP Morgan Chase reported no remaining Cyclerion Therapeutics position as of Q4 2021 after selling out during the quarter.
  • JP Morgan Chase sold 2,067 Cyclerion Therapeutics shares in Q4 2021, an estimated $127K.
  • JP Morgan Chase first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 10 quarters.
  • JP Morgan Chase's Cyclerion Therapeutics position peaked at $332K in Q3 2020.
  • 56 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2021.

Based on JP Morgan Chase's 13F filing for Q4 2021, filed 10 Feb 2022.